JP2018514523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514523A5 JP2018514523A5 JP2017553915A JP2017553915A JP2018514523A5 JP 2018514523 A5 JP2018514523 A5 JP 2018514523A5 JP 2017553915 A JP2017553915 A JP 2017553915A JP 2017553915 A JP2017553915 A JP 2017553915A JP 2018514523 A5 JP2018514523 A5 JP 2018514523A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- ribocyclic
- rib
- ribocyclib
- succinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012156 elution solvent Substances 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562148240P | 2015-04-16 | 2015-04-16 | |
| US62/148,240 | 2015-04-16 | ||
| PCT/IB2016/052136 WO2016166703A1 (en) | 2015-04-16 | 2016-04-14 | Ribociclib tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018514523A JP2018514523A (ja) | 2018-06-07 |
| JP2018514523A5 true JP2018514523A5 (enExample) | 2019-05-23 |
Family
ID=55806565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553915A Pending JP2018514523A (ja) | 2015-04-16 | 2016-04-14 | リボシクリブ錠剤 |
Country Status (31)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4772247A2 (en) | 2013-08-14 | 2026-07-08 | Novartis AG | Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer |
| SI4197530T1 (sl) * | 2015-04-16 | 2026-03-31 | Novartis Ag | Tableta ribocikliba |
| CA3048036A1 (en) | 2018-07-02 | 2020-01-02 | Apotex Inc | Crystalline form of ribociclib succinate |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| IL293940B2 (en) | 2019-12-16 | 2026-05-01 | Lunella Biotech Inc | Selective cancer drugs CDK4/6 inhibitors |
| EP4077325B1 (en) | 2019-12-16 | 2026-03-11 | Lunella Biotech, Inc. | Selective cdk4/6 inhibitor cancer therapeutics |
| WO2022029798A1 (en) * | 2020-08-03 | 2022-02-10 | Natco Pharma Limited | Pharmaceutical compositions comprising ribociclib |
| MX2022015336A (es) * | 2020-09-29 | 2023-01-11 | Laboratorios Silanes S A De C V | Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares. |
| WO2022162122A1 (en) | 2021-01-29 | 2022-08-04 | Biotx.Ai Gmbh | Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection |
| CN117396208A (zh) | 2021-07-16 | 2024-01-12 | 达纳－法伯癌症研究所公司 | 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法 |
| TWI908143B (zh) | 2022-01-25 | 2025-12-11 | 瑞士商諾華公司 | 瑞博西尼藥物組成物用於治療癌症之用途 |
| WO2024049926A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
| JP2026513185A (ja) | 2023-03-27 | 2026-04-23 | ノバルティス アーゲー | アロマターゼ阻害薬との組み合わせでのリボシクリブによる早期乳癌の治療方法 |
| US20250319032A1 (en) | 2024-04-15 | 2025-10-16 | Novartis Ag | Pharmaceutical compositions of ribociclib |
| WO2026128391A1 (en) | 2024-12-09 | 2026-06-18 | Arvinas Operations, Inc. | Combinations of vepdegestrant and cdk4/6 inhibitors for treating esr1-mutant breast cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5428812A (en) * | 1977-08-09 | 1979-03-03 | Yoshitomi Pharmaceut Ind Ltd | Preparation of coated tablet |
| GB9414045D0 (en) | 1994-07-12 | 1994-08-31 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
| EP0771339B1 (en) * | 1994-07-12 | 2003-10-15 | BPSI Holdings, Inc. | Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith |
| US6448323B1 (en) * | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| US8784781B2 (en) * | 2009-09-24 | 2014-07-22 | Mcneil-Ppc, Inc. | Manufacture of chewing gum product with radiofrequency |
| CU20090172A7 (es) * | 2009-10-09 | 2011-10-05 | Ct De Investigación Y Desarrollo De Medicamentos | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular |
| AR083797A1 (es) * | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
| KR101888713B1 (ko) * | 2011-02-11 | 2018-08-14 | 위스타 레보레이토리스 리미티드 | 페노티아진 디아미늄 염 및 이의 용도 |
| EP3733170A1 (en) * | 2012-07-13 | 2020-11-04 | Oncternal Therapeutics, Inc. | A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms) |
| EP2742940B1 (en) * | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
| EP2934515B1 (en) * | 2012-12-20 | 2018-04-04 | Novartis AG | A pharmaceutical combination comprising binimetinib |
| US9913844B2 (en) * | 2013-03-21 | 2018-03-13 | Novartis Ag | Combination therapy |
| EP2810644A1 (en) * | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
| SI4197530T1 (sl) * | 2015-04-16 | 2026-03-31 | Novartis Ag | Tableta ribocikliba |
| CN109953966A (zh) * | 2017-12-26 | 2019-07-02 | 天津耀辰实业发展有限公司 | 一种含有瑞博西尼的药物组合物及其制备方法 |
| JP7347388B2 (ja) | 2020-09-25 | 2023-09-20 | 信越化学工業株式会社 | 紫外線硬化型有機変性シリコーン組成物および硬化物 |
-
2016
- 2016-04-14 SI SI201631943T patent/SI4197530T1/sl unknown
- 2016-04-14 RS RS20260107A patent/RS67697B1/sr unknown
- 2016-04-14 FI FIEP22203730.1T patent/FI4197530T3/fi active
- 2016-04-14 HR HRP20230053TT patent/HRP20230053T1/hr unknown
- 2016-04-14 ES ES16718020T patent/ES2938261T3/es active Active
- 2016-04-14 CN CN201680022122.8A patent/CN107530292B/zh active Active
- 2016-04-14 KR KR1020177029433A patent/KR102750931B1/ko active Active
- 2016-04-14 PE PE2017002096A patent/PE20180035A1/es unknown
- 2016-04-14 FI FIEP16718020.7T patent/FI3283058T3/fi active
- 2016-04-14 PL PL22203730.1T patent/PL4197530T3/pl unknown
- 2016-04-14 US US15/564,534 patent/US10799506B2/en active Active
- 2016-04-14 CN CN202211237232.XA patent/CN115554257A/zh active Pending
- 2016-04-14 EA EA201792290A patent/EA201792290A1/ru unknown
- 2016-04-14 WO PCT/IB2016/052136 patent/WO2016166703A1/en not_active Ceased
- 2016-04-14 EP EP16718020.7A patent/EP3283058B1/en active Active
- 2016-04-14 SI SI201631661T patent/SI3283058T1/sl unknown
- 2016-04-14 BR BR112017021283-8A patent/BR112017021283A2/en not_active Application Discontinuation
- 2016-04-14 MX MX2017013350A patent/MX2017013350A/es unknown
- 2016-04-14 PT PT222037301T patent/PT4197530T/pt unknown
- 2016-04-14 ES ES22203730T patent/ES3062263T3/es active Active
- 2016-04-14 IL IL254818A patent/IL254818B1/en unknown
- 2016-04-14 IL IL327430A patent/IL327430A/en unknown
- 2016-04-14 AU AU2016248017A patent/AU2016248017A1/en not_active Abandoned
- 2016-04-14 DK DK22203730.1T patent/DK4197530T3/da active
- 2016-04-14 SG SG11201708084PA patent/SG11201708084PA/en unknown
- 2016-04-14 LT LTEP22203730.1T patent/LT4197530T/lt unknown
- 2016-04-14 AR ARP160101012A patent/AR104257A1/es unknown
- 2016-04-14 EP EP22203730.1A patent/EP4197530B1/en active Active
- 2016-04-14 JP JP2017553915A patent/JP2018514523A/ja active Pending
- 2016-04-14 PT PT167180207T patent/PT3283058T/pt unknown
- 2016-04-14 TN TNP/2017/000422A patent/TN2017000422A1/en unknown
- 2016-04-14 PL PL16718020.7T patent/PL3283058T3/pl unknown
- 2016-04-14 KR KR1020257000051A patent/KR20250009572A/ko active Pending
- 2016-04-14 DK DK16718020.7T patent/DK3283058T3/da active
- 2016-04-14 EP EP25194967.3A patent/EP4620458A3/en active Pending
- 2016-04-14 HU HUE16718020A patent/HUE061213T2/hu unknown
- 2016-04-14 HR HRP20260123TT patent/HRP20260123T1/hr unknown
- 2016-04-14 CA CA2982425A patent/CA2982425C/en active Active
- 2016-04-15 TW TW105111921A patent/TW201642864A/zh unknown
-
2017
- 2017-10-04 PH PH12017501820A patent/PH12017501820A1/en unknown
- 2017-10-13 CO CONC2017/0010510A patent/CO2017010510A2/es unknown
- 2017-10-13 CL CL2017002593A patent/CL2017002593A1/es unknown
- 2017-11-10 EC ECIEPI201775052A patent/ECSP17075052A/es unknown
-
2019
- 2019-03-20 AU AU2019201929A patent/AU2019201929B2/en active Active
-
2020
- 2020-08-26 US US17/003,771 patent/US20200390771A1/en not_active Abandoned
- 2020-10-06 AU AU2020250190A patent/AU2020250190A1/en not_active Abandoned
-
2022
- 2022-06-08 US US17/805,956 patent/US12064434B2/en active Active
- 2022-08-08 AU AU2022215155A patent/AU2022215155B2/en active Active
-
2024
- 2024-02-27 US US18/588,259 patent/US20250090531A1/en active Pending
- 2024-10-31 AU AU2024227794A patent/AU2024227794A1/en active Pending
- 2024-12-11 US US18/977,210 patent/US20250134893A1/en active Pending
- 2024-12-11 US US18/977,228 patent/US12419894B2/en active Active